HOUSTON–IPS HEART, a privately held cell therapy company advancing its stem cell platform to develop new skeletal muscle and cardiac muscle generation treatments for Duchenne muscular dystrophy (a rare disease) and heart failure, today announced that the U.S. Food and Drug Administration (FDA) awarded a third Rare Pediatric Drug Designation (RPDD) for its product candidate, ISX9-CPC, for treatment of cardiomyopathy associated with Danon disease. ISX9-CPC stem cell therapeutic candidate is designed to create new functional human heart muscle along with reducing cardiac fibrosis. [Read more…]
Cord Blood
Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.
StemInov Will Bioproduct the First Cell Therapy Drug to Treat Inflammatory Diseases
NANCY-STRASBOURG, France –StemInov, a biotechnology company developing an innovative biomedicine based on stem cells from umbilical cords to treat inflammatory diseases, septic shock and acute respiratory distress syndrome (ARDS), will bioproduct the first cell therapy drug from umbilical cord stem. In this context, StemInov’s promising disruptive innovations has been selected to join the French Tech – Health20 program launched by the French Government that will accelerate the development of StemInov’s proprietary and collaborative programs with greater visibility in France and internationally. [Read more…]
ImmuneBridge Raises $12M from M Ventures and Insight Partners to Advance Cord Blood-Derived NK Cell Immunotherapies
Biotech company taps into human diversity for next-generation NK cell therapies
SAN FRANCISCO–ImmuneBridge, a biotechnology company using nature’s innate intelligence to fight cancer, today announced the close of an oversubscribed $12 million seed financing co-led by global investors Insight Partners and M Ventures, the strategic, corporate venture capital arm of Merck KGaA, Darmstadt, Germany. One Way Ventures and Gaingels also participated. Cheryl Zimberlin, Investment Director at M Ventures, and Dylan Morris, Managing Director at Insight Partners have joined ImmuneBridge’s Board of Directors. [Read more…]
iPSirius Granted Second American Patent for Innovative IPVAC Cancer Vaccine Technology
Paris, March 7 2023 – iPSirius, a leading biotechnology company focused on the development of innovative immunotherapies, announced that it has been granted its second American patent for a novel technology that enables the production of ‘off-the-shelf’ cancer vaccines from induced pluripotent stem cells (iPSCs). [Read more…]
Pairing Cord Blood and Tissue Storage with Genetic Testing Services
One of the most prominent trends within the global cord blood banking industry is the pairing of cord blood and tissue storage with pre- and post-natal testing services, including genetic testing, genome sequencing, and metabolic screening services. The rise of this trend is driven by the ability of cord blood storage providers to offer complimentary services to existing clients, thereby expanding and diversifying their product portfolio.
As one cord blood executive recently told me, “They are looking to extend the relationship with the mother.” [Read more…]
- « Previous Page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- …
- 62
- Next Page »